Source-grounded facts extracted from PRECISION BIOSCIENCES INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PRECISION BIOSCIENCES INC: Amended certificate of incorporation to provide for exculpation of certain officers as permitted by Delaware law (effective 2026-05-22).
“On May 22, 2026, the Company filed the 2026 Amendment with the Secretary of State of the State of Delaware, and the 2026 Amendment became effective upon filing.”
PRECISION BIOSCIENCES INC reported financial results for first quarter ended March 31, 2026.
“Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.”
Sam Wadsworth resigned as Director at PRECISION BIOSCIENCES INC.
“On January 23, 2025, Sam Wadsworth, Ph.D., notified Precision BioSciences, Inc. (the “Company”) of his intention to retire from service on company boards and resigned from the Company’s Board of Directors.”
Alan List departed as Chief Medical Officer at PRECISION BIOSCIENCES INC.
“On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.”
PRECISION BIOSCIENCES INC terminated Amended and Restated Development and License Agreement with Prevail Therapeutics Inc. valued at Termination without cause upon 90 days notice (effective 2024-04-11).
“On April 11, 2024, Precision BioSciences, Inc. (the “Company”) received written notice from Prevail Therapeutics Inc. (“Prevail”), a wholly-owned subsidiary of Eli Lilly and Company, of Prevail’s termination of the Amended and Restated Development and License Agreement, dated June 30, 2023, between Prevail and the Company (the “Agreement”).”
PRECISION BIOSCIENCES INC reported financial results for quarter and fiscal year ended December 31, 2023.
“On March 27, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.”
PRECISION BIOSCIENCES INC: Amended certificate of incorporation to effect a 1-for-30 reverse stock split (effective 2024-02-13).
“On February 13, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the “Certificate of Amendment”) to amend the Certificate of Incorporation to effect the Reverse Stock Split.”
PRECISION BIOSCIENCES INC shareholders approved Approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies at the 2024-01-18 meeting.
“Proposal 2 – The approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1. Votes FOR Votes AGAINST Votes ABSTAINED BROKER NON-VOTES 75,291,080 7,698,338 339,229 0”
PRECISION BIOSCIENCES INC shareholders approved Approval of amendments to the company's amended and restated certificate of incorporation to effect a reverse stock split of the company's common stock at a ratio ranging from 1-for-10 to 1-for-30 at the 2024-01-18 meeting.
“Proposal 1 – The approval of amendments to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s Common Stock at a ratio ranging from any whole number between 1-for-10 and 1-for-30, as determined by the Company’s Board of Directors (the “Board”) in its discretion, subject to the Board’s authority to abandon such amendments. Votes FOR Votes AGAINST Votes ABSTAINED BROKER NON-VOTES 71,771,593 11,275,251 281,803 0”
PRECISION BIOSCIENCES INC entered into License Agreement with TG Cell Therapy, Inc. and TG Therapeutics, Inc. valued at upfront cash payment of $10.0 million (effective 2024-01-07).
“On January 7, 2024 (the “Effective Date”), Precision BioSciences, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with TG Cell Therapy, Inc. (“TG Subsidiary”) and its parent company TG Therapeutics, Inc. (“TG Parent” and, together with TG Subsidiary, “TG Therapeutics”), pursuant to which the Company granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize non-oncological applications of the Company’s allogeneic CAR T therapy azer-cel (collectively, the “Licensed Product”) pursuant to the terms of the License Agreement.”
PRECISION BIOSCIENCES INC: Amended and restated bylaws to address universal proxy rules, update stockholder nomination and proposal procedures, and make technical changes (effective 2023-12-19).
“On December 19, 2023, the Board of Directors (the “Board”) of Precision BioSciences, Inc. (the “Company”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.